Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Shares Issued (2018 - 2025)

Zevra Therapeutics' Shares Issued history spans 9 years, with the latest figure at -$6.0 million for Q4 2025.

  • For Q4 2025, Shares Issued changed N/A year-over-year to -$6.0 million; the TTM value through Sep 2025 reached $6.0 million, up 595800.0%, while the annual FY2023 figure was $218000.0, N/A changed from the prior year.
  • Shares Issued reached -$6.0 million in Q4 2025 per ZVRA's latest filing, down from $3.0 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $25.6 million in Q1 2021 to a low of -$6.0 million in Q4 2025.
  • Average Shares Issued over 5 years is $3.9 million, with a median of $682500.0 recorded in 2023.
  • Peak YoY movement for Shares Issued: plummeted 623.29% in 2024, then skyrocketed 362.65% in 2025.
  • A 5-year view of Shares Issued shows it stood at $10.7 million in 2021, then plummeted by 102.02% to -$216000.0 in 2022, then surged by 99.54% to -$1000.0 in 2023, then plummeted by 114500.0% to -$1.1 million in 2024, then plummeted by 419.81% to -$6.0 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Shares Issued are -$6.0 million (Q4 2025), $3.0 million (Q3 2025), and $2.9 million (Q2 2025).